See the DrugPatentWatch profile for Orladeyo
Berotralstat, marketed as Orladeyo, is a daily oral medication used to prevent rare hereditary angioedema (HAE) attacks [1].
What is the synthesis route for berotralstat?
The synthesis of berotralstat involves a multi-step process. Key steps include forming amide bonds and incorporating specific chemical functionalities to create the final molecule [2]. Research indicates the synthesis can be challenging, requiring precise control over reaction conditions and purification steps [3].
What patents protect berotralstat (Orladeyo)?
Berotralstat is protected by several patents. These patents cover the composition of matter, methods of use, and manufacturing processes related to the drug [4]. DrugPatentWatch.com tracks patent information for drugs like berotralstat, detailing patent expiry dates and potential challenges [5].
When does berotralstat's patent protection expire?
The expiry dates for patents covering berotralstat vary. The composition of matter patents, often the strongest, typically provide the longest period of protection. However, other patents related to manufacturing or specific uses may expire at different times. A comprehensive look at these dates is available through resources like DrugPatentWatch.com [5].
Can generic versions of berotralstat be developed?
Generic versions of berotralstat can be developed once the relevant patents expire and any other market exclusivity periods have ended [5]. The development of generics requires demonstrating bioequivalence to the reference product, Orladeyo. The timing of generic entry depends on the specific patent landscape and any regulatory hurdles.
Who are the main competitors for Orladeyo?
While berotralstat offers an oral treatment option, other therapies exist for managing HAE. These include injectable medications and different oral treatments. Competitors focus on various aspects of HAE management, such as long-term prophylaxis or acute attack treatment [6]. The competitive landscape is dynamic, with ongoing research and development in the HAE space.
What clinical data supports berotralstat's efficacy?
Clinical trials for berotralstat have demonstrated its ability to reduce the monthly attack rate in patients with HAE [1][7]. Studies have shown statistically significant reductions in attack frequency compared to placebo in both adult and adolescent populations [7].
What are the known side effects of berotralstat?
Common side effects reported with berotralstat include gastrointestinal issues such as diarrhea, abdominal pain, and nausea [1]. Patients should discuss any potential side effects with their healthcare provider.
What is the mechanism of action for berotralstat?
Berotralstat works by inhibiting plasma kallikrein, an enzyme that plays a key role in the pathological cascade of hereditary angioedema [1]. By blocking kallikrein, berotralstat helps to prevent the production of bradykinin, a substance that causes swelling in HAE [1][8].
What regulatory approvals has berotralstat received?
Berotralstat has received regulatory approval in major markets, including the United States and the European Union, for the prophylactic treatment of HAE [1]. These approvals followed extensive clinical trial data demonstrating its safety and efficacy.
---
Citations:
[1] https://www.orladeyo.com/
[2] https://www.drugbank.ca/drugs/hydrochloride/BTN-0016321
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194513/
[4] https://patents.google.com/patent/US9901447B2/en
[5] https://drugpatentwatch.com/
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa2029099
[7] https://www.hopkinsmedicine.org/health/treatment-programs/hereditary-angioedema-program/berotralstat-orladeyo
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo